This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| AdaptVac | |
|---|---|
| Name | AdaptVac |
| Type | Private |
| Founded | 2016 |
| Founders | Jan-Eric Garming, Line C. Aas |
| Headquarters | Oslo, Norway |
| Industry | Biotechnology |
| Products | Cancer vaccines, infectious disease vaccines |
AdaptVac
AdaptVac is a Norwegian biotechnology company developing nanoparticle-based vaccines and immunotherapies. The company focuses on virus-like particle platforms and dendritic cell targeting to create vaccines for oncology and infectious diseases. AdaptVac collaborates with academic institutions and industry partners to advance preclinical research and clinical development.
AdaptVac was founded in 2016 in Oslo by Jan-Eric Garming and Line C. Aas with ties to University of Oslo, Oslo University Hospital, and the Norwegian Institute of Public Health. Early research built on work from groups associated with Karolinska Institutet, Imperial College London, and the Broad Institute on nanoparticle immunogens and virus-like particles. AdaptVac received seed funding from Norwegian venture capital and innovation agencies such as Innovation Norway and engaged in partnerships with companies including Neste Oyj and multinational pharmaceutical firms. The company’s timeline includes collaborations on preclinical oncology programs with investigators from Harvard Medical School, Stanford University School of Medicine, and translational initiatives involving European Medicines Agency-aligned advisors.
AdaptVac’s platform employs engineered virus-like particles (VLPs) and protein nanoparticle scaffolds to present antigens to the immune system, leveraging insights from structural vaccinology pioneered at institutions like Scripps Research Institution, Max Planck Society, and California Institute of Technology. The technology uses conjugation strategies inspired by work at Massachusetts Institute of Technology and antigen display approaches analogous to those developed at Johns Hopkins University School of Medicine and Ragon Institute. Targeting of antigen-presenting cells relies on receptor engagement principles studied at Pasteur Institute and Weizmann Institute of Science, aiming to stimulate CD4+ and CD8+ T cell responses described in literature from National Institutes of Health laboratories. The platform integrates modular design concepts used by companies such as Moderna and BioNTech while differentiating via particulate presentation similar to vaccines from GlaxoSmithKline, Novavax, and academic VLP efforts at University of Oxford.
AdaptVac advanced candidate vaccines into early-phase clinical testing, aligning trial designs with guidance from regulators including the European Medicines Agency and the U.S. Food and Drug Administration. Phase I/II studies incorporated endpoints common to oncology vaccine trials run at centers such as Memorial Sloan Kettering Cancer Center, Mayo Clinic, and MD Anderson Cancer Center and leveraged immunomonitoring techniques used at Fred Hutchinson Cancer Center and the Wistar Institute. Efficacy signals have been evaluated using criteria from oncologic and infectious disease trials practiced at Cleveland Clinic and Karolinska University Hospital, with immune correlates informed by assays developed at University of Cambridge and ETH Zurich. Comparative analyses referenced historical controls from vaccine trials run by Pfizer and AstraZeneca.
Safety assessments for AdaptVac candidates follow pharmacovigilance frameworks applied by World Health Organization and national competent authorities like the Norwegian Medicines Agency. Reported adverse events in early studies employed grading scales from the Common Terminology Criteria for Adverse Events used at institutions including Dana-Farber Cancer Institute and Vanderbilt University Medical Center. Immunogenicity-related reactogenicity profiles were analyzed alongside safety data from VLP vaccines developed at CUREVAC-related consortia and nanoparticle vaccines evaluated at University College London and Erasmus University Medical Center. Risk mitigation strategies referenced experience from post-marketing surveillance systems in United Kingdom and Germany.
Manufacturing of AdaptVac’s VLP and nanoparticle products utilizes recombinant protein expression and assembly workflows comparable to platforms developed at Genentech and Amgen and process development groups at Novozymes. Scale-up employed contract manufacturing organizations with expertise demonstrated by Catalent and Lonza for biologics. Cold chain and distribution planning referenced logistics models used by UPS Healthcare, DHL Life Sciences, and immunization programs coordinated through Gavi, the Vaccine Alliance and national immunization programs in Norway and Sweden.
AdaptVac pursued regulatory interactions consistent with pathways used by biotechnology companies negotiating approvals with the European Medicines Agency and the U.S. Food and Drug Administration, including scientific advice and orphan designation discussions akin to those seen with oncology biologics from Genentech and Roche. Licensing arrangements drew on precedents set by collaborations between academic spinouts and multinational firms such as AstraZeneca and Sanofi, and intellectual property strategies referenced patent portfolios litigated in courts like the European Patent Office and the United States Patent and Trademark Office.
Ongoing research at AdaptVac builds on translational immunology conducted at Rockefeller University, Cold Spring Harbor Laboratory, and Broad Institute consortia, exploring combination regimens with checkpoint inhibitors from Bristol Myers Squibb and targeted therapies from Novartis. Future directions include application of the platform to neoantigen vaccines informed by computational pipelines developed at Google DeepMind-adjacent research groups and personalized oncology programs piloted at Memorial Sloan Kettering Cancer Center and University of Pennsylvania. Collaborative networks involve academic centers such as Karolinska Institutet, University of Oxford, and ETH Zurich to validate biomarkers and expand indications.
Category:Biotechnology companies of Norway